Study: NCT02278250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 450 mg BIW
Description: Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 700 mg BIW
Description: Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 1050 mg BIW
Description: Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 1200 mg BIW
Description: Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 100 mg BID
Description: Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 150 mg QD
Description: Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 250 mg QD
Description: Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 250 mg QD
Description: Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 350 mg QD
Description: Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 350 mg QD
Description: Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 400 mg
Description: Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 500 mg
Description: Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.